Literature DB >> 28378556

RNA-Seq for Gene Expression Profiling of Human Necrotizing Enterocolitis: a Pilot Study.

Kyuwhan Jung1, Insong Koh2, Jeong Hyun Kim3, Hyun Sub Cheong4, Taejin Park5, So Hyun Nam6, Soo Min Jung7, Cherry Ann Sio8, Su Yeong Kim6, Euiseok Jung9, Byoungkook Lee9, Hye Rim Kim9, Eun Shin10, Sung Eun Jung11, Chang Won Choi9, Beyong Il Kim9, Eunyoung Jung12, Hyoung Doo Shin3,13.   

Abstract

Necrotizing enterocolitis (NEC) characterized by inflammatory intestinal necrosis is a major cause of mortality and morbidity in newborns. Deep RNA sequencing (RNA-Seq) has recently emerged as a powerful technology enabling better quantification of gene expression than microarrays with a lower background signal. A total of 10 transcriptomes from 5 pairs of NEC lesions and adjacent normal tissues obtained from preterm infants with NEC were analyzed. As a result, a total of 65 genes (57 down-regulated and 8 up-regulated) revealed significantly different expression levels in the NEC lesion compared to the adjacent normal region, based on a significance at fold change ≥ 1.5 and P ≤ 0.05. The most significant gene, DPF3 (P < 0.001), has recently been reported to have differential expressions in colon segments. Our gene ontology analysis between NEC lesion and adjacent normal tissues showed that down-regulated genes were included in nervous system development with the most significance (P = 9.3 × 10⁻⁷; P(corr) = 0.0003). In further pathway analysis using Pathway Express based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, genes involved in thyroid cancer and axon guidance were predicted to be associated with different expression (P(corr) = 0.008 and 0.020, respectively). Although further replications using a larger sample size and functional evaluations are needed, our results suggest that altered gene expression and the genes' involved functional pathways and categories may provide insight into NEC development and aid in future research.
© 2017 The Korean Academy of Medical Sciences.

Entities:  

Keywords:  Gene Expression; Necrotizing Enterocolitis; RNA-Seq

Mesh:

Substances:

Year:  2017        PMID: 28378556      PMCID: PMC5383615          DOI: 10.3346/jkms.2017.32.5.817

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


INTRODUCTION

Necrotizing enterocolitis (NEC) characterized by intestinal ischemia and necrosis is one of the most common gastrointestinal emergencies in premature infants with very low birth weights (VLBWs), i.e., those who weigh less than 1,500 g (123). NEC affects about 5%–14% of VLBW neonates. Since NEC is a life-threatening gastrointestinal disease and an unpredictable surgical emergency, the overall mortality from NEC is high, ranging from 25% to 40% (45). Many researchers have tried to determine the precise pathophysiology of NEC by examining the various mechanisms that influence NEC development, such as the interaction between intraluminal microbiology and enteral nutrition and the change in inflammatory response by proinflammatory cytokines (67891011). Although several studies have been conducted and their associated hypotheses tested, substantial evidence to confirm risk factors (and effective therapies) for NEC has yet to be determined (1213), other than prematurity and low birth weight (14). Although several studies suggest that genetic factors affect NEC development in preterm infants with a potential susceptibility to NEC (1516), the mechanisms underlying NEC are not fully understood. Previously, an NEC mice model has been used in many studies to establish the causes of or risk factors for human NEC due to several limitations in using human subjects, such as necrosis of human intestinal tissues and nonspecific inflammatory changes (17). However, although the animal models contribute to our understanding of disease mechanisms, limitations of reliability and reproducibility make the use of such models controversial (1819). Since transcripts are crucial intermediaries between the genome and the proteome, the detection of global gene expression is an important method for understanding molecular mechanisms of diseases and specific functions of particular tissues. Although microarray-based gene expression analysis has become the primary high-throughput platform in the past decade, this method has certain limitations, including high background noise and low resolution (20). Recently, RNA sequencing (RNA-Seq), using high-throughput next-generation sequencing methods, has become a powerful technology providing robust quantification of gene expression levels with a low background signal and high resolution (2122).

MATERIALS AND METHODS

Study subjects

Study subjects were collected from Seoul National University Bundang Hospital, Gyemyoung University Dongsan Hospital, National Gyeongsang University Hospital, Donga University Hospital, and CHA University Bundang Hospital in Korea. The study protocol was approved by the institutional review board of the hospital, and written informed consent was provided by guardians of all patients. Premature infants at less than 32 weeks of gestational age and less than 1,500 g birth weight were enrolled in this study. Two tissue sections (NEC lesion and adjacent normal regions) from the resected small bowel segment were collected as follows: 1) an NEC lesion that showed perforation or necrosis; and 2) adjacent normal tissue. Next, the tissues were immediately stored in liquid nitrogen until RNA extraction at −80°C; a portion of the tissues was evaluated by histological examination. Before RNA extraction, the mucosal layers of each tissue section were collected by the pediatric surgeon who performed the operation on the infants.

RNA isolation and quality control

Total RNA was extracted from the dissected tissue sections (NEC lesion and adjacent normal regions) with the Nucleo-Spin-RNA-II-Kit (Macherey-Nagel, Düren, Germany) according to the manufacturer's protocol. RNA integrity and purity were analyzed with the Experion™ automated electrophoresis system (Bio-Rad, Hercules, CA, USA) with the Experion RNA StdSens chip. The mRNA was extracted and purified from the total RNA with the TruSeq stranded mRNA HT sample preparation kit (Illumina, Inc., San Diego, CA, USA), and this was followed by a purity check with Qubit 2.0 fluorometer (Life Technologies, Waltham, MA, USA) before proceeding to cDNA synthesis.

RNA-Seq and data analysis

RNA-Seq was carried out in order to identify differentially expressed genes in the NEC lesion and adjacent normal tissues. The isolated mRNA from 4 μg total RNA using oligo-dT magnetic beads was fragmented and primed at 94°C for 8 minutes, and then prepared for sequencing according to the protocol of the TruSeq stranded mRNA HT sample preparation kit (Illumina, Inc.). The resulting complementary DNA (cDNA) libraries were sequenced on the Illumina MiSeq system with 75 bp paired-end reads using the Illumina MiSeq sequencing kit v3 (150 cycles; Illumina, Inc.) following the manufacturer's instructions. Image processing and base calling were performed using the Illumina Real Time Analysis Software RTA v1.9.35. FastQ sequences were aligned to the human genome database (NCBI37/hg19) using TopHat v.2.0.12 with default parameters. The reads were mapped using the gene models as provided in the annotation GTF file (GRCh37.75). Gene expression values were determined using Cufflinks 2.2.1 release (http://cole-trapnell-lab.github.io/cufflinks/), and the FPKM (fragments per kilobase of exon per million fragments mapped) values were calculated for each transcript. Cufflinks default settings were adopted, and FPKM values were computed by summing the values of different transcripts of the same gene. To identify differentially expressed genes, a fold change over 1.5 between any pairwise comparisons was applied. For statistical analysis, data were examined by t-test.

Ethics statement

The present study protocol was reviewed and approved by the Institutional Review Board of Seoul National University Bundang Hospital (IRB No. B-1404-245-008). Informed consent was submitted by guardians of all patients.

RESULTS

Patients

A total of 5 NEC patients, with median gestational ages of 26 weeks and 2 days, birth weight of 922 g, and birth height of 34.2 cm, were enrolled in this study. None of the patients showed other congenital anomalies in the perinatal period, and the mothers had no antenatal/perinatal problems except for premature delivery. The exploratory laparotomy was performed in the NEC patients at a median gestational age of 29 weeks and 1 day. The operations included a segmental resection with temporary ileostomy or primary anastomosis. All patients recovered from NEC and survived without complications. Following surgery, a histological examination of NEC lesion and adjacent normal tissues from the patients was performed (Fig. 1).
Fig. 1

NEC tissues for experiment and histological features. Arrows indicate 2 tissue sections (NEC lesion and adjacent normal regions) from the resected small bowel segment and each histological examination.

NEC = necrotizing enterocolitis.

NEC tissues for experiment and histological features. Arrows indicate 2 tissue sections (NEC lesion and adjacent normal regions) from the resected small bowel segment and each histological examination. NEC = necrotizing enterocolitis.

RNA-Seq analysis and gene expression comparison

To investigate the gene expression profiles for NEC development in preterm infants, RNA-Seq analysis using the Illumina MiSeq system was performed. Mapping of sequences resulted in an average read count of 11.75 × 106 (± 4.36×106) in 10 RNA samples composed of those from 2 paired small-bowel sections (NEC lesion and adjacent normal tissues) from each of 5 NEC patients. Of the 23,972 tested genes, a total of 65 genes (57 down-regulated and 8 up-regulated) were observed to have significantly different expression levels in the comparison between NEC lesion and adjacent normal tissues, based on a significance at fold change ≥ 1.5 and P ≤ 0.05 (Table 1). As a housekeeping gene, GAPDH was measured as 1,320.16 in NEC lesion and 1,255.20 in adjacent normal tissue (fold change = 1.05).
Table 1

Down-/up-regulated genes in comparison of NEC lesion and adjacent normal tissues

No.Down-/up-regulationGeneLocusExpression level (FPKM, average)Fold change (NEC lesion/adjacent normal)P value
NEC lesion (n = 5)Adjacent normal (n = 5)
1DownHTR3AChr11:113845796-1138610340.712.430.290.030
2DownCPLX2Chr5:175223609-1753110230.381.090.350.040
3DownPCP4Chr21:41239346-4130132212.9836.340.360.050
4DownPCSK2Chr20:17206751-174652220.391.080.360.030
5DownST8SIA6Chr10:17362675-174962540.531.390.380.050
6DownSLC5A7Chr2:108602994-1086304431.523.980.380.050
7DownPCDHGA6Chr5:140753650-1408925460.441.110.400.050
8DownTMIEChr3:46742822-467524130.451.130.400.050
9DownDNAJC6Chr1:65730376-658815521.694.180.400.030
10DownELAVL4Chr1:50513685-506675405.6413.810.410.050
11DownSULT4A1Chr22:44220386-442583782.245.440.410.040
12DownATRNL1Chr10:116853123-1177084960.591.380.430.050
13DownRETChr10:43572516-436257973.387.740.440.040
14DownSPOCK2Chr10:73818791-738487904.049.010.450.007
15DownPTGES3LChr17:41120104-411325451.653.660.450.040
16DownPTPRRChr12:71031852-713145841.713.760.450.030
17DownCHODLChr21:19289656-196396870.791.730.460.010
18DownNRXN3Chr14:78636715-803346332.966.470.460.050
19DownPIRTChr17:10725791-107414180.731.580.460.050
20DownSCUBE1Chr22:43599228-437393940.571.210.470.020
21DownBZRAP1-AS1Chr17:56402810-564310881.072.250.480.020
22DownCAMK4Chr5:110559946-1108207481.903.990.48< 0.001
23DownACTG2Chr2:74120092-74146780155.56322.230.480.050
24DownFAM226BChrX:72161567-721635890.541.110.490.040
25DownLOC151174Chr2:239133753-2391403180.641.310.490.050
26DownMBNL1-AS1Chr3:151980404-1519874152.535.050.500.050
27DownIQCH-AS1Chr15:67695948-678141821.462.900.500.020
28DownCDK5R1Chr17:30814104-308182711.132.230.510.010
29DownFOXN3-AS1Chr14:89883697-898861370.941.850.510.030
30DownDPF3Chr14:73136659-733608090.531.040.51< 0.001
31DownPTPRZ1Chr7:121513158-1217020902.985.700.520.020
32DownSH3GL2Chr9:17578952-177971220.731.370.530.050
33DownSEPT6ChrX:118749687-11882733314.0226.020.540.050
34DownCTNND2Chr5:10971951-119041100.761.410.540.020
35DownBAI3Chr6:69345631-700994031.352.480.540.040
36DownRUNDC3AChr17:42385926-423960384.468.180.550.040
37DownARNT2Chr15:80696691-808902771.913.420.560.030
38DownSEMA4FChr2:74881354-749109810.711.260.560.020
39DownFAM161BChr14:74399694-744171171.152.040.560.050
40DownRPS6KL1Chr14:75370656-753891450.631.110.570.020
41DownGRIP1Chr12:66741210-670729250.891.560.570.020
42DownMACROD2Chr20:13976145-160338410.470.820.570.010
43DownVAMP1Chr12:6571403-65798433.886.760.570.040
44DownC3orf70Chr3:184795837-1848708025.028.490.590.040
45DownRBM38Chr20:55966453-5598438612.6420.810.610.020
46DownTSPAN11Chr12:31079837-311495370.681.110.610.020
47DownLRRC4CChr11:40135750-414811861.732.810.620.030
48DownBCL11AChr2:60678301-607806332.834.470.630.050
49DownMANEALChr1:38259773-382672781.492.330.640.050
50DownMOXD1Chr6:132617193-1327226645.438.390.650.030
51DownJAZF1Chr7:27870192-282204377.1010.870.650.050
52DownTENM3Chr4:183245136-1837241771.612.430.660.010
53DownPCDHB2Chr5:140474236-1404769641.101.650.670.050
54DownPODXL2Chr3:127348001-1273916534.857.290.670.040
55DownKLHL23Chr2:170590355-1706083968.8013.150.670.050
56DownGPC4ChrX:132435063-13254920513.2719.310.690.030
57DownPRKCEChr2:45879042-464151293.625.260.690.050
58UpWT1Chr11:32409321-324570811.480.393.820.050
59UpSPAG4Chr20:34203808-342089651.650.841.970.030
60UpADAMTS14Chr10:72432558-725221953.872.051.890.040
61UpGHRLOSChr3:10322635-103351331.020.551.850.030
62UpDSTNP2Chr12:6993845-69949504.342.351.850.020
63UpZNF503-AS2Chr10:77161285-771687401.070.681.570.030
64UpGBAP1Chr1:155183615-1551973255.973.911.530.030
65UpMCOLN1Chr19:7587495-75988959.506.221.530.020
GAPDH*Chr12:6643584-66475371320.161255.201.05-

“-” in the fold change indicates down regulation.

NEC = necrotizing enterocolitis, Chr = chromosome.

*GAPDH indicates a housekeeping gene.

“-” in the fold change indicates down regulation. NEC = necrotizing enterocolitis, Chr = chromosome. *GAPDH indicates a housekeeping gene. Among the differentially expressed genes in NEC lesions compared to the adjacent normal region, double PHD fingers 3 (DPF3, P < 0.001) and calcium/calmodulin-dependent protein kinase IV (CAMK4, P < 0.001) showed relatively robust association signals of upregulation, whereas downregulated genes showed weak signals (Table 1). In addition, 3 genes (PCP4, PTPRR, and WT1), which were recently reported as potential genes of NEC, were also observed to be differentially expressed in the NEC lesion (Table 1).

Ontology and pathway analyses of differentially expressed genes in NEC

To assess the biological functions of the differentially expressed genes in NEC lesions and adjacent normal tissues, this study performed a gene ontology analysis using the WEB-based GEne SeT AnaLysis Toolkit (http://bioinfo.vanderbilt.edu/webgestalt/). As a result, 16 gene ontology categories (14 in biological processes and 2 in the cellular component) were predicted to affect NEC development in humans (Table 2), with the most significant signal at nervous system development (P = 9.3 × 10-7; P = 0.0003). In additional pathway analysis using Pathway Express (http://vortex.cs.wayne.edu/projects.htm) based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, genes involved in thyroid cancer and axon guidance showed significant associations (Table 3, P = 0.008 and 0.02, respectively).
Table 2

Gene ontology analysis of differentially expressed genes in comparison of NEC lesion and adjacent normal tissues

Down-/up-regulationCategoryGene ontology categoryObserved genesObserved genes numberExpected genes numberRatio of enrichmentSignificance of enrichment
P valueCorrected P value
DownBiological processNervous system developmentDPF3, LRRC4C, PCSK2, MACROD2, RET, PCP4, PCDHB2, CDK5R1, BCL11A, NRXN3, SEMA4F, SH3GL2, PTPRR, PTPRZ1, CPLX2, ARNT2, SPOCK2174.713.619.3 × 10−7< 0.001
DownBiological processNeuron cell-cell adhesionCTNND2, CDK5R1, RET30.0391.444.1 × 10−60.001
DownBiological processSystem developmentDPF3, LRRC4C, PCSK2, MACROD2, RET, CAMK4, PCP4, PCDHB2, CHODL, CDK5R1, RBM38, BCL11A, NRXN3, BAI3, SH3GL2, SEMA4F, SCUBE1, PTPRR, CPLX2, PTPRZ1, ARNT2, TMIE, SPOCK2239.632.396.0 × 10−60.002
DownBiological processSynaptic transmissionNRXN3, SH3GL2, VAMP1, HTR3A, CPLX2, CAMK4, GRIP1, SLC5A7, PCDHB2, CTNND2101.785.627.2 × 10−60.003
DownBiological processSingle-multicellular organism processDPF3, LRRC4C, PCSK2, MACROD2, RET, CAMK4, SLC5A7, PCP4, PCDHB2, CHODL, ACTG2, CDK5R1, RBM38, BCL11A, NRXN3, BAI3, SH3GL2, VAMP1, SEMA4F, SCUBE1, PTPRR, HTR3A, CPLX2, PTPRZ1, GRIP1, ARNT2, TMIE, SPOCK2, CTNND22915.341.891.2 × 10−50.004
DownBiological processMulticellular organismal processDPF3, LRRC4C, PCSK2, MACROD2, RET, CAMK4, SLC5A7, PCP4, PCDHB2, CHODL, ACTG2, CDK5R1, RBM38, BCL11A, NRXN3, BAI3, SH3GL2, VAMP1, SEMA4F, SCUBE1, PTPRR, HTR3A, CPLX2, PTPRZ1, GRIP1, ARNT2, TMIE, SPOCK2, CTNND22915.431.881.4 × 10−50.005
DownBiological processAnatomical structure developmentDPF3, LRRC4C, PCSK2, MACROD2, RET, CAMK4, PCP4, PCDHB2, CHODL, CDK5R1, RBM38, BCL11A, NRXN3, BAI3, SH3GL2, SEMA4F, SCUBE1, PTPRR, CPLX2, PTPRZ1, ARNT2, TMIE, SPOCK2, CTNND22411.022.181.7 × 10−50.006
DownBiological processMulticellular organismal developmentDPF3, LRRC4C, PCSK2, MACROD2, RET, CAMK4, PCP4, PCDHB2, CHODL, CDK5R1, RBM38, BCL11A, NRXN3, BAI3, SH3GL2, SEMA4F, SCUBE1, PTPRR, CPLX2, PTPRZ1, ARNT2, TMIE, SPOCK2, CTNND22411.152.152.1 × 10−50.007
DownBiological processTransmission of nerve impulseNRXN3, SH3GL2, VAMP1, HTR3A, CPLX2, CAMK4, GRIP1, SLC5A7, PCDHB2, CTNND2102.014.982.1 × 10−50.007
DownBiological processMulticellular organismal signalingNRXN3, SH3GL2, VAMP1, HTR3A, CPLX2, CAMK4, GRIP1, SLC5A7, PCDHB2, CTNND2102.054.872.5 × 10−50.009
DownBiological processNeurotransmitter secretionNRXN3, SLC5A7, VAMP1, CPLX240.2714.78< 0.0010.030
DownBiological processCell-cell signalingNRXN3, SH3GL2, SEMA4F, VAMP1, HTR3A, CPLX2, CAMK4, GRIP1, SLC5A7, PCDHB2, CTNND2113.003.66< 0.0010.030
DownCellular componentSynapseSEMA4F, VAMP1, SEPT6, HTR3A, CPLX2, GRIP1, CDK5R1, CTNND281.206.642.2 × 10−50.002
DownCellular componentSynapse partGRIP1, SEMA4F, VAMP1, SEPT6, CTNND2, CDK5R1, HTR3A70.917.683.0 × 10−50.002
UpBiological processExtracellular structure organizationADAMTS14, WT120.0634.500.0010.030
UpBiological processExtracellular matrix organizationADAMTS14, WT120.0634.670.0010.030

Gene ontology categories with corrected P value of enrichment significance below 0.05 are shown.

NEC = necrotizing enterocolitis.

Table 3

Potential pathways affected by differentially expressed genes in comparisons of NEC lesion and adjacent normal tissues

Pathway nameDifferentially regulated genesInput genes in pathway, %Impact factorCorrected P value
Thyroid cancerRET1.5876.9140.008
Axon guidanceLRRC4C, SEMA4F3.1755.7400.020

Corrected P value is obtained using the classical hypergeometric model (32).

NEC = necrotizing enterocolitis.

Gene ontology categories with corrected P value of enrichment significance below 0.05 are shown. NEC = necrotizing enterocolitis. Corrected P value is obtained using the classical hypergeometric model (32). NEC = necrotizing enterocolitis.

DISCUSSION

Acquired conditions of diffuse necrotic injury to the intestinal segments are known to affect NEC development. Abnormal bacterial colonization and formula feeding have also been implicated as predisposing factors for NEC in humans (2324). In addition, potential associations between NEC and environmental factors (such as microbiome, microbiome-intestinal reaction to breast milk or formula milk feeding, vaginal or cesarean section mode of delivery, and antibiotics) have been reported (1011232425). Interestingly, a significant reduction of NEC in infants who were fed breast milk, compared to those who were fed formula, has been reported (26). Thus, many neonatologists have gone to great effort to manage the microbiome to prevent NEC development. Many neonatologists in Korea have changed their management protocols for preterm infants and observed a decreased incidence of NEC during the last few years. NEC development may be multifactorial with the interplay between intrinsic and extrinsic factors. In addition, the main risk factor for NEC development in premature infants is thought to be intestinal immaturity (2327), suggesting that intrinsic risk factors may be more important because premature infants have had a short exposure time to external environments. In this study, we hypothesized that global gene expression profiling may reveal distinct genetic differences between NEC lesion and adjacent normal region. Although candidate genes in this study did not reach great values of significance, several potential genes (such as DPF3 and CAMK4) with relatively robust association signals were identified (P < 0.001). These markers may have a role in NEC development. However, further replication and evaluation studies are needed. As noted, this study showed relatively robust association signals at DPF3 and CAMK4. DPF3, which is known as an epigenetic key factor for the development of heart and muscle tissue, has been reported to play a role in the neuronal differentiation process and also to take part in the disassembly of muscular fibers (28). In the different colon segments of Hirschsprung's disease, the gene product of DPF3 has been observed to be lowly expressed in a stenotic segment, whereas it is highly expressed in proximal anastomosis (29), suggesting that DPF3 may be dysregulated in colonic diseases such as NEC. In the case of CAMK4, although a direct association between CAMK4 and NEC has not been reported, several connections in the literature related to necrosis can be found. In particular, CAMK4 was observed to be involved in the necrosis factor (NF)-kappaB mediated signaling pathway in human endothelial cells (30). These previous results and our findings suggest that dysregulated expressions of genes identified in this study may contribute to NEC development. Recently, the first RNA-Seq for gene expression profiling in NEC was reported (31). This first RNA-Seq study used ileum tissues from preterm patients with other diseases for the control, and several genes associated with immune functions (in particular, genes associated with Crohn's disease) were identified as contributing factors to NEC development, together with other candidate genes. When compared to our results, PCP4 and PTPRR were overlapped; however, no connections in the literature related to NEC or related cellular functions (such as necrosis) could be found. Therefore, further studies are required to elucidate the association between these potential genes and NEC development. So as to remove the heterogeneity of genetic background, this study excluded non-Korean parents. However, the study also has several limitations, such as insufficient sample size and lack of functional evaluation. The small sample size was due to the overall decreased incidence of NEC. In addition, normal tissues from the small bowel segment in infants without NEC or related diseases would have been ideal for the comparison analysis; however, it was limited to obtain these normal tissues. Although the first RNA-Seq analysis study of NEC used the ileum for the normal control (31), this study used adjacent normal tissues, and we do not rule out the possible effect of congenital diseases (such as small intestinal perforation, intestinal atresia, etc.). In conclusion, despite study limitations, our preliminary results have identified potential involvements of certain genes (such as DPF3 and CAMK4) in NEC development, suggesting that these genetic factors, perhaps together with epigenetic factors such as microbiomes and breast milk, may have a role in NEC development in humans. Further validation studies are needed to determine clinical applications of these potential targets.
  32 in total

1.  PLC/CAMK IV-NF-kappaB involved in the receptor for advanced glycation end products mediated signaling pathway in human endothelial cells.

Authors:  Jie You; Wei Peng; Xu Lin; Qing-Ling Huang; Jian-Yin Lin
Journal:  Mol Cell Endocrinol       Date:  2010-02-18       Impact factor: 4.102

2.  Repeatability of published microarray gene expression analyses.

Authors:  John P A Ioannidis; David B Allison; Catherine A Ball; Issa Coulibaly; Xiangqin Cui; Aedín C Culhane; Mario Falchi; Cesare Furlanello; Laurence Game; Giuseppe Jurman; Jon Mangion; Tapan Mehta; Michael Nitzberg; Grier P Page; Enrico Petretto; Vera van Noort
Journal:  Nat Genet       Date:  2008-01-28       Impact factor: 38.330

Review 3.  Necrotising enterocolitis.

Authors:  Patricia W Lin; Barbara J Stoll
Journal:  Lancet       Date:  2006-10-07       Impact factor: 79.321

4.  The epidemiology of necrotizing enterocolitis infant mortality in the United States.

Authors:  R C Holman; B J Stoll; M J Clarke; R I Glass
Journal:  Am J Public Health       Date:  1997-12       Impact factor: 9.308

5.  Impact of necrotizing enterocolitis on length of stay and hospital charges in very low birth weight infants.

Authors:  Jennifer A Bisquera; Timothy R Cooper; Carol Lynn Berseth
Journal:  Pediatrics       Date:  2002-03       Impact factor: 7.124

6.  Neurodevelopmental and growth outcomes of extremely low birth weight infants after necrotizing enterocolitis.

Authors:  Susan R Hintz; Douglas E Kendrick; Barbara J Stoll; Betty R Vohr; Avroy A Fanaroff; Edward F Donovan; W Kenneth Poole; Martin L Blakely; Linda Wright; Rosemary Higgins
Journal:  Pediatrics       Date:  2005-03       Impact factor: 7.124

7.  Can animal models of disease reliably inform human studies?

Authors:  H Bart van der Worp; David W Howells; Emily S Sena; Michelle J Porritt; Sarah Rewell; Victoria O'Collins; Malcolm R Macleod
Journal:  PLoS Med       Date:  2010-03-30       Impact factor: 11.069

Review 8.  RNA-Seq: a revolutionary tool for transcriptomics.

Authors:  Zhong Wang; Mark Gerstein; Michael Snyder
Journal:  Nat Rev Genet       Date:  2009-01       Impact factor: 53.242

9.  16S rRNA gene-based analysis of fecal microbiota from preterm infants with and without necrotizing enterocolitis.

Authors:  Yunwei Wang; Jeanette D Hoenig; Kathryn J Malin; Sanaa Qamar; Elaine O Petrof; Jun Sun; Dionysios A Antonopoulos; Eugene B Chang; Erika C Claud
Journal:  ISME J       Date:  2009-04-16       Impact factor: 10.302

Review 10.  Epidemiology of necrotizing enterocolitis.

Authors:  B J Stoll
Journal:  Clin Perinatol       Date:  1994-06       Impact factor: 3.430

View more
  3 in total

1.  Global hypermethylation of intestinal epithelial cells is a hallmark feature of neonatal surgical necrotizing enterocolitis.

Authors:  Misty Good; Tianjiao Chu; Patricia Shaw; Lora McClain; Austin Chamberlain; Carlos Castro; Jamie M Rimer; Belgacem Mihi; Qingqing Gong; Lila S Nolan; Krista Cooksey; Laura Linneman; Pranjal Agrawal; David N Finegold; David Peters
Journal:  Clin Epigenetics       Date:  2020-12-11       Impact factor: 6.551

2.  A Pilot Study To Establish an In Vitro Model To Study Premature Intestinal Epithelium and Gut Microbiota Interactions.

Authors:  Justin Gibbons; Ji Youn Yoo; Tina Mutka; Maureen Groer; Thao T B Ho
Journal:  mSphere       Date:  2021-10-13       Impact factor: 4.389

3.  Anti-inflammatory actions of acetate, propionate, and butyrate in fetal mouse jejunum cultures ex vivo and immature small intestinal cells in vitro.

Authors:  Shengnan Huang; Yanan Gao; Ziwei Wang; Xue Yang; Jiaqi Wang; Nan Zheng
Journal:  Food Sci Nutr       Date:  2022-01-18       Impact factor: 2.863

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.